First Capital Advisors Group’s Gilead Sciences GILD Stock Holding History

First Capital Advisors Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$535K	Sell	6,947 -120	-2%	-$9.57K	0.28%	71
2023 Q1	$586K	Buy	7,067 +22	+0.3%	+$1.82K	0.38%	67
2022 Q4	$605K	Sell	7,045 -1,086	-13%	-$86K	0.41%	68
2022 Q3	$502K	Buy	8,131 +1,185	+17%	+$74.7K	0.42%	66
2022 Q2	$429K	Buy	+6,946	New	+$430K	0.29%	83
2018 Q4	$497K	Sell	7,945 -1,323	-14%	-$92.5K	0.37%	60
2018 Q3	$716K	Buy	9,268 +398	+4%	+$30.1K	0.44%	50
2018 Q2	$628K	Buy	8,870 +1,150	+15%	+$81.2K	0.42%	54
2018 Q1	$582K	Sell	7,720 -137	-2%	-$10.9K	0.34%	66
2017 Q4	$563K	Buy	7,857 +653	+9%	+$49.6K	0.36%	74
2017 Q3	$584K	Buy	7,204 +2,442	+51%	+$187K	0.4%	69
2017 Q2	$337K	Buy	+4,762	New	+$317K	0.23%	110

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Capital Advisors Group's GILD Position: Q2 2023 in Review

First Capital Advisors Group reduced its Gilead Sciences (GILD) stake by 1.7% in Q2 2023, selling an estimated $9.57K and leaving 6,947 shares worth $535K. The position accounts for 0.28% of the portfolio, ranked #71.

First Capital Advisors Group first reported a position in GILD in Q2 2017 and has held it in 12 quarters since. The position peaked at $716K in Q3 2018. 1,701 funds tracked by Wall St. Rank hold GILD as of Q2 2023.

First Capital Advisors Group held 6,947 shares of Gilead Sciences worth $535K as of Q2 2023.
First Capital Advisors Group sold 120 Gilead Sciences shares in Q2 2023, an estimated $9.57K.
Gilead Sciences made up 0.28% of First Capital Advisors Group's portfolio in Q2 2023, its #71 holding.
First Capital Advisors Group first reported a position in Gilead Sciences in Q2 2017 and has held it in 12 quarters since.
First Capital Advisors Group's Gilead Sciences position peaked at $716K in Q3 2018.
1,701 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.